BridgeMD
New treatment option for ST-segment Elevation Myocardial Infarction (STEMI)
Official title Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction
ClinicalTrials.gov ID: NCT04912518
What this study is testing
What is Dexmedetomidine (DEX)?
Dexmedetomidine (DEX) is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for st-segment elevation myocardial infarction (stemi).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a double-blind, multicenter, randomized, placebo-controlled clinical trial. It is planned to enroll patients admitted with anterior ST-segment elevation myocardial infarction (STEMI) within 6h of symptom onset and undergo primary percutaneous coronary intervention (pPCI).
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- the enrolled people must meet all of the following criteria:
- Aged 18-75 years old (inclusive);
- Diagnosed with anterior STEMI within 6h of symptom onset: (1) ischemic chest discomfort; (2) electrocardiogram (ECG) with ST elevation ≥0.2 mV in 2...
- Sign the informed consent form.
You likely can't join if
- people who meet any one of the following criteria are excluded from the study:
- Ventricular fibrillation, cardiogenic shock, Killip III-IV grade;
- Sinus bradycardia (heart rate sustained \ 240ms or II-III degree atrioventricular block;
- Continuous systolic blood pressure \<120mmHg;
- Severe breathing difficulties, aterial blood oxygen saturation \<92%;
- Thrombolytic therapy has been performed before the first medical contact in the hospital;
See the full eligibility criteria
- the enrolled people must meet all of the following criteria:
- Aged 18-75 years old (inclusive);
- Diagnosed with anterior STEMI within 6h of symptom onset: (1) ischemic chest discomfort; (2) electrocardiogram (ECG) with ST elevation ≥0.2 mV in 2 or more contiguous precordial leads (one of which should be V2, V3, or...
- Sign the informed consent form.
- people who meet any one of the following criteria are excluded from the study:
- Ventricular fibrillation, cardiogenic shock, Killip III-IV grade;
- Sinus bradycardia (heart rate sustained \ 240ms or II-III degree atrioventricular block;
- Continuous systolic blood pressure \<120mmHg;
- Severe breathing difficulties, aterial blood oxygen saturation \<92%;
- Thrombolytic therapy has been performed before the first medical contact in the hospital;
- Consciousness disorder or past cerebrovascular disease;
- Previous history of myocardial infarction or PCI/CABG treatment;
- Known severe liver and kidney dysfunction;
- Known allergy to dexmedetomidine;
- CMR contraindications: such as claustrophobia, pacemaker or ICD implantation;
- Pregnant or lactating women;
- Malignant tumor or expected survival time \<1 year;
- Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study (eg, poor compliance, inability of the patient to comply with study procedures...
- Participate in other assigned by chance controlled studies at the same time.
The study team makes the final eligibility decision.
Where it's taking place
- Hefei, Anhui, China
- Lanzhou, Gansu, China
- Harbin, Heilongjiang, China
- Mudanjiang, Heilongjiang, China
- Zhengzhou, Henan, China
- Wuhan, Hubei, China
- Xi'an, Shaanxi, China
- Taiyuan, Shanxi, China
- Tianjin, Tianjin Municipality, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hefei, Anhui, China; Lanzhou, Gansu, China; Harbin, Heilongjiang, China; Mudanjiang, Heilongjiang, China; Zhengzhou, Henan, China; Wuhan, Hubei, China and 3 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.